Related Experiment Video
Updated: Jan 2, 2026

Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
Glycogen synthase kinase 3β hyperactivity in urinary exfoliated cells predicts progression of diabetic kidney disease
Xianhui Liang1, Pei Wang2, Bohan Chen3
1Blood Purification Center, Institute of Nephrology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China; Department of Medicine, Division of Kidney Disease and Hypertension, Rhode Island Hospital, Brown University School of Medicine, Providence, Rhode Island, USA.
Abstract:
Burgeoning evidence points to glycogen synthase kinase (GSK)3β as a key player in diverse kidney diseases. However, as a pivotal transducer of the insulin signaling pathway, the role of GSK3β in diabetic kidney disease remains uncertain. In db/db mice, renal expression of total and activated GSK3β was increasingly elevated. This preceded the development of diabetic kidney disease, and correlated with the progression of signs of diabetic kidney injury, including albuminuria and extracellular matrix accumulation in glomeruli and tubulointerstitia. In vitro, exposure of glomerular podocytes, mesangial cells, and renal tubular cells to a diabetic milieu induced GSK3β overexpression and hyperactivity, which seem essential and sufficient for eliciting diabetic cellular damages in kidney cells, because the cytopathic effect of the diabetic milieu was mitigated by GSK3β knockdown, but was mimicked by ectopic expression of constitutively active GSK3β even in the normal milieu. In consistency, kidney biopsy specimens procured from patients with varying stages of diabetic nephropathy revealed an amplified expression of total and activated GSK3β in glomeruli and renal tubules, associated with the severity of diabetic nephropathy. Moreover, in retrospective cohorts of type 2 diabetic patients that were followed for over five years, the relative activity of GSK3β in banked urinary exfoliated cells represented an independent risk factor for development or progression of renal impairment. Furthermore, receiver operating characteristic curve analysis demonstrated that GSK3β activity in urinary exfoliated cells provided much better power than albuminuria in discriminating diabetic patients with progressive renal impairment from those with stable kidney function. Thus, renal expression and activity of GSK3β are amplified in experimental and clinical diabetic nephropathy. Hence, GSK3β in urinary exfoliated cells may serve as a novel biomarker for predicting diabetic kidney disease progression.
Insights
Glycogen synthase kinase 3 beta (GSK3β) is elevated in diabetic kidney disease. Its activity in urinary cells may predict kidney function decline in diabetic patients, suggesting it as a potential biomarker.
Area of Science:
- Nephrology
- Endocrinology
- Molecular Biology
Background:
- Glycogen synthase kinase 3 beta (GSK3β) is implicated in various kidney diseases.
- Its specific role in diabetic kidney disease (DKD) is not fully understood, despite its function in insulin signaling.
Purpose of the Study:
- To investigate the role and significance of GSK3β in the pathogenesis and progression of diabetic kidney disease.
- To evaluate GSK3β as a potential biomarker for predicting renal impairment in diabetic patients.
Main Methods:
- Assessed renal expression and activity of GSK3β in db/db mice models of DKD.
- Utilized in vitro cell cultures (podocytes, mesangial, tubular cells) exposed to a diabetic milieu.
- Analyzed kidney biopsy specimens from patients with diabetic nephropathy and retrospectively studied urinary exfoliated cells from type 2 diabetic patients.
Main Results:
- Elevated total and activated GSK3β in the kidneys of db/db mice preceded DKD development and correlated with injury markers.
- Diabetic milieu induced GSK3β hyperactivity in kidney cells, causing damage that was reversible by GSK3β inhibition or mimicked by its activation.
- Increased GSK3β expression in human kidney biopsies correlated with DKD severity.
- Urinary GSK3β activity independently predicted renal impairment progression in type 2 diabetic patients and outperformed albuminuria in discriminating progressive vs. stable DKD.
Conclusions:
- Renal GSK3β expression and activity are significantly amplified in experimental and clinical diabetic nephropathy.
- GSK3β plays a critical role in the cellular damage associated with DKD.
- Urinary GSK3β activity emerges as a promising novel biomarker for predicting the progression of diabetic kidney disease.
Related Concept Videos
Urine Studies I: Urinalysis
Chronic Kidney Disease I: Introduction
Chronic Kidney Disease III: Interprofessional Care

